2024 ELCC Highlights

CME

Highlights From the 2024 ELCC Annual Congress

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 26, 2024

Expiration: December 25, 2024

Activity

Progress
1 2
Course Completed

Introduction

In this module, Luis Paz-Ares, MD, PhD, and Zofia Piotrowska, MD, discuss key findings in the management of lung cancer presented at the 2024 European Lung Cancer Congress (ELCC), including updates in early-stage and advanced non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with lung cancer do you provide care for in a typical month?

The phase III PACIFIC-2 trial compared adding durvalumab or placebo to concurrent chemoradiotherapy (CRT) followed by consolidation durvalumab or placebo in patients with unresectable stage III NSCLC. At ELCC 2024, which of the following findings was reported in the durvalumab arm vs placebo arm?

The phase III EMPOWER-Lung 3 Part 1 trial compared first-line treatment with a quadruplet regimen comprising cemiplimab plus platinum doublet chemotherapy plus ipilimumab vs chemotherapy alone in patients with advanced NSCLC and PD-L1 <50%. According to an exploratory analysis at ELCC 2024, which of the following best describes results from the quadruplet regimen vs chemotherapy alone for most patient-reported outcomes?

When counseling a patient with advanced NSCLC harboring an EGFR exon 19 deletion, how would you best describe the overall survival (OS) and postprogression outcomes reported at ELCC 2024 from the FLAURA2 trial comparing first-line osimertinib plus chemotherapy vs osimertinib alone in patients with EGFR-mutated advanced NSCLC?

Based on evidence from the DeLLphi-300 and 301 trials, which of the following agents would be most likely to benefit a patient with relapsed extensive-stage SCLC and stable, asymptomatic brain metastases?